Two Sigma Advisers
VIR icon

Two Sigma Advisers’s Vir Biotechnology VIR Stock Holding History

Two Sigma Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-577,700
Closed -$3.48M – 2086
2025
Q4 		$3.48M Buy
577,700
+73,700
+15% +$439K 0.01% 970
2025
Q3 		$2.88M Buy
504,000
+189,100
+60% +$967K 0.01% 966
2025
Q2 		$1.59M Buy
314,900
+202,200
+179% +$1.08M ﹤0.01% 1227
2025
Q1 		$730K Buy
112,700
+37,900
+51% +$337K ﹤0.01% 1613
2024
Q4 		$549K Buy
74,800
+32,000
+75% +$252K ﹤0.01% 1741
2024
Q3 		$321K Sell
42,800
-30,700
-42% -$267K ﹤0.01% 1884
2024
Q2 		$654K Buy
+73,500
New +$705K ﹤0.01% 1775
2023
Q4 		– Sell
-15,900
Closed -$149K – 2655
2023
Q3 		$149K Buy
+15,900
New +$227K ﹤0.01% 2151
2023
Q2 		– Sell
-10,900
Closed -$254K – 2674
2023
Q1 		$254K Buy
+10,900
New +$279K ﹤0.01% 2199

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Two Sigma Advisers's VIR Position: Q1 2026 in Review

Two Sigma Advisers sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 577,700 shares — an estimated $3.48M sold.

Two Sigma Advisers first reported a position in VIR in Q1 2023 and held it in 9 quarters. The position peaked at $3.48M in Q4 2025. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Two Sigma Advisers reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 577,700 Vir Biotechnology shares in Q1 2026, an estimated $3.48M.
  • Two Sigma Advisers first reported a position in Vir Biotechnology in Q1 2023 and held it in 9 quarters.
  • Two Sigma Advisers's Vir Biotechnology position peaked at $3.48M in Q4 2025.
  • 252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.